Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupHead and Neck OncologyradiotherapyDiseaseHead and Neck Tumors (Squamous Cell)Nasopharyngeal CarcinomaSubgroupHPV positiveICD10C11.-C11.8C11.9C76.0MeSHHypopharyngeal NeoplasmsLaryngeal NeoplasmsMouth NeoplasmsNasopharyngeal CarcinomaOropharyngeal NeoplasmsSquamous Cell Carcinoma of Head and NeckSequenceCETU400/PACL40/CRBP2/Radiation, Head and Neck Tumors, C1 (PID622) -|- CETU250/PACL40/CRBP2/Radiation, Head and Neck Tumors, C2+ (PID621)CETU400/PACL90/CRBP2, Head and Neck Tumors, C1 (PID1242) -|- C2-6 (PID1243) -|- C7-11 (PID1244)CETU400/Radiation, Head and Neck Tumors, C1 (PID1194) -|- CETU250/Radiation, C2+ (PID1195)CISP12/FU600/Radiation, Head and Neck Tumors, C1-2 (PID2059) -|- C3 (PID2060) -|- C4 (PID2062)CISP100/Radiatio, Head and Neck Tumors (PID1334) -|- CISP100/CAPE1000, Nasopharyngeal Ca (PID1784).DOCE60/CISP60/FU600, Nasopharyngeal Ca (PID1373) -|- CISP100/Radiation, Head and Neck Tumors (PID1334)DOCE75/CISP75/FU750, Head and Neck Tumors (PID1102) -|- CRBP1.5/Radiation (PID1282)GEMC1000/CISP80, Nasopharyngeal Ca (PID1325) -|- CISP100/Radiation (PID1334)ChemotherapyChemo-substanceCarboplatinCetuximabCisplatinDocetaxelFluorouracilMitomycinPaclitaxelPembrolizumabChemo-substanceCarboplatinCetuximabCisplatinDocetaxelFluorouracilMitomycinPaclitaxelPembrolizumabChemo-substanceCarboplatinCetuximabCisplatinDocetaxelFluorouracilMitomycinPaclitaxelPembrolizumabChemo-substanceCarboplatinCetuximabCisplatinDocetaxelFluorouracilMitomycinPaclitaxelPembrolizumabNo. Substances123 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMinocyclinePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMinocyclinePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMinocyclinePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMinocyclinePegfilgrastimPotassium chlorideNo. Substances12345678Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineTherapy phaseInductionneoadjuvantPre-phaseTherapy intentioncurativepalliativeRisksAllergic ReactionAnemia Hb below 8g/dlAstheniaCardiotoxicityConstipationDehydrationDiarrheaDysphagiaEmetogenicity (MASCC/ESMO)EsophagitisExanthema, AcneiformFatigueFebrile NeutropeniaGastrointestinal ToxicityHepatotoxicityHypertensionHyperthyroidismHypomagnesemiaHyponatremiaInfectionsLeukopeniaLymphopeniaMucositisNephrotoxicityNeurotoxicityNeutropeniaOral MucositisOtotoxicityPainPneumoniaPyrexiaRadiation DermatitisRashRenal FailureSepsisThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorAdelstein D Bonner JBonner JBrizel DMBudach V Calais GCooper JGhi MHaddad RMaring SMedina JAMehanna HNoronha VPatil VMPosner MSuntharalingam MTao Y Vermorken JWanebo HDiseasefortgeschrittener Kopf-Hals-Tumor, Erstlinie, Stadium III-IV, ECOG 0-1fortgeschrittenes Oropharynxkarzinom, nicht metastasiert, Stadium III-IV, Karnofsky <60Karzinom des Oro- und, Hypopharynx, Larynx, Stadium III und IV, nicht metastasiert, Erstlinie, Karnofsky > 60Kopf-Hals-Tumor,nicht-metastasiert, cisplatinungeeignet, ECOG 0-1Kopf-Hals-Tumoren (Plattenepithel-), adjuvant, ECOG 0-1Kopf-Hals-Tumoren (Plattenepithel-), resektabel, Stadium III-IV, ECOG 0-1Kopf-Hals-Tumoren, cTx cNx cM0, nicht cisplatingeeignet, ECOG 0-2Kopf-Hals-Tumoren, nicht resektabel, UICC Stadium III/IV, ECOG 0-1Kopf-Hals-Tumoren, Plattenepithel-Ca, cT3/cT4, cN0-3, cM0 (bei Zungengrund-Ca max. cT2cN0), 18-75J., ECOG 0-2Kopf-Hals-Tumoren, Stadium III -IV, nicht metastasiert, Erstlinie, ECOG 0-1Kopf-Hals-Tumoren, Stadium III oder IV, ohne Fernmetastasen, Erstlinientherapie, ECOG 0-2Lokal fortgeschrittene Kopf-Hals-Tumoren, Stadium III und IV, adjuvant oder definitive Chemo-Radiotherapie ECOG 0-2lokal fortgeschrittenes, nicht reserzierbares Plattenepithel-Karzinom des Kopf/Halses, Stadium III-IV,M0 Erstlinie, Karnofsky >70Lokal fortgeschrittenes, nicht resezierbares Plattenepithelzellkarzinom des Kopf-Hals-BereichsNeudiagnostizierter, lokal fortgeschrittener Kopf-Hals-Tumor, Stadium III-IV, Plattenepithel-, ECOG 0-1neudiagnostizierter, lokal fortgeschrittener Kopf-Hals-Tumor, Stadium III-IV, Plattenepithel-, ECOG 0-1Nicht resezierbare Kopf-Hals-Tumoren (Plattenepithel-), Stadium III - IV, ECOG 0-1Oropharynxkarzinom (Plattenepithel), HPV-positiv und low-risk (nie Raucher oder weniger als 10 PY), T3N0–T4N0, and T1N1–T4N3, ECOG 0-1OriginCentre Hospitalier Universitaire Tours, France, 94-01 French Head and Neck Oncology and Radiotherapy GroupCleveland Clinic Foundation, ClevelandDana–Farber Cancer Institute, Boston, TAX 324 Study GroupDepartment of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai, IndiaDepartment of Medicine, University of Alabama, BirminghamDepartment of Radiation Oncology, University Hospital of Muenster, Muenster, GermanyDepartment of Radiation Oncology, University of Maryland School of Medicine, Baltimore BDDepartment of Surgery, Landmark Medical Center, Woonsocket, ECOG-ACRIN trial (E2303)Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, USAGORTEC 2015-01 PembroRadHead and Neck Oncology, Dana Farber Cancer Institute, arvard Medical School, Boston, MassachusettsInstitute for Head and Neck Studies and Education (InHANSE), University of Birmingham, UK, De-ESCALaTE HPV trialMedical Oncology Department, Ospedale dell’Angelo, Venezia, the GSTTC Italian Study GroupNew York University Medical Center, New York, Radiation Therapy Oncology Group 9501/IntergroupServicio de Oncologia Radioterapica, Hospital Clinico Universitario, Malaga, SpainTata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, IndiaUniversitair Ziekenhuis Antwerpen, Edegem, BelgiumUniversity Hospitals Charite, Berlin, German Cancer Society 95-06 trialProtocols in Revision 22 protocols foundProtocols under revision.Carboplatin 1.5 / Radiation, Head and Neck Tumors (PID1282)Carboplatin 70 / Fluorouracil 600 / Radiation, Oropharyngeal Carcinoma (PID1708)Cetuximab 250 / Paclitaxel 30 / Carboplatin 1 / Radiation, Head and Neck Tumors, Cycle 7-11 (PID1244)Cetuximab 250 / Paclitaxel 40 / Carboplatin 2 / Radiation, Head and Neck Tumors, Cycle 2+ (PID621)Cetuximab 250 / Radiation, Head and Neck Tumors, Cycle 2+ (PID1195)Cetuximab 400 / Paclitaxel 40 / Carboplatin 2 / Radiation, Head and Neck Tumors, Cycle 1 (PID622)Cetuximab 400 / Radiation, Head and Neck Tumors, Cycle 1 (PID1194)Cisplatin 100 / Radiation, Head and Neck Tumors (PID1334)Cisplatin 100 / Radiation, Head and Neck Tumors (PID1640)Cisplatin 100 / Radiation, Head and Neck Tumors, adjuvant (PID1291)Cisplatin 12 / Fluorouracil 600 / Radiation, Head and Neck Tumors, cycle 1-2 (PID2059)Cisplatin 16 / fluorouracil 600, Head and Neck Tumors, cycle 3 (PID2060)Cisplatin 20 / Fluorouracil 600, Head and Neck Tumors, cycle 4 (PID2062)Cisplatin 20 / Fluorouracil 800 / Radiation, Head and Neck Tumors (PID2066)Cisplatin 30 / Radiation, Head and Neck Tumors, adjuvant (PID1240)Cisplatin 40 / Radiation, Head and Neck Tumors (PID1637)Docetaxel 15 / Radiatio, Head and Neck Tumors (PID2259)Docetaxel 75 / Cisplatin 75 / Fluorouracil 750, Head and Neck Tumors (PID1102)Fluorouracil 600 / Mitomycin 10 / Radiation, Head and Neck Tumors (PID2058)Paclitaxel 40 / Carboplatin 1 / Radiation, Head and Neck Tumors (PID2386)Paclitaxel 45 / Carboplatin 1.5 / Radiation, Head and Neck Tumors (PID1295)Pembrolizumab 200 / Radiation, Head and Neck Tumors (PID2258)
